BRAF and thyroid cancer: Due to the important position of CXCL8 in PTC, Coperchini et al. designed some experiments to test the effect of the BRAF inhibitor (PLX4720) on the basal and TNF-α-induced CXCL8 secretions in BRAFV600E-mutated (BCPAP, 8305C, and 8505C) and RET/PTC-rearranged (TPC-1) thyroid cancer cell lines and in normal human thyrocytes (NHT).